4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-056320
Chief Accounting Officer sold 403 shares at $1.63 ($657)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hagen Brett R · Chief Accounting Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-11-17 | Sale : show line 1 in the form 10b5-1 | −403 | $1.63 | $657 | 125,835 | D |
| Open-market sales · 403 sh · avg $1.63 · $657 | ||||||
Loading xslF345X05/doc4.xml…